12/22
08:02 am
hscs
HeartSciences (NASDAQ:HSCS) had its price target raised by analysts at Ascendiant Capital Markets from $9.00 to $9.20. They now have a "buy" rating on the stock.
Low
Report
HeartSciences (NASDAQ:HSCS) had its price target raised by analysts at Ascendiant Capital Markets from $9.00 to $9.20. They now have a "buy" rating on the stock.
12/15
06:47 pm
hscs
Heart Test Laboratories reports Q2 results [Seeking Alpha]
High
Report
Heart Test Laboratories reports Q2 results [Seeking Alpha]
12/15
04:15 pm
hscs
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
High
Report
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
12/15
08:30 am
hscs
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
High
Report
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
12/11
09:13 am
hscs
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 [Yahoo! Finance]
Medium
Report
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 [Yahoo! Finance]
12/11
08:30 am
hscs
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
Medium
Report
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1
10/14
12:15 pm
hscs
HeartSciences (NASDAQ:HSCS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
HeartSciences (NASDAQ:HSCS) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/4
12:07 am
hscs
Low
Report
10/1
08:06 am
hscs
HeartSciences (NASDAQ:HSCS) had its price target lowered by analysts at Ascendiant Capital Markets from $15.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
HeartSciences (NASDAQ:HSCS) had its price target lowered by analysts at Ascendiant Capital Markets from $15.00 to $9.00. They now have a "buy" rating on the stock.